Hostname: page-component-7b7567c8c-wxvwp Total loading time: 0 Render date: 2026-11-18T03:44:28.122Z Has data issue: false hasContentIssue false

Orofacial Dyskinesia, Cognitive Function and Medication

Published online by Cambridge University Press:  29 January 2018

Philip Thomas*
Affiliation:
Department of Psychiatry, The Royal Edinburgh Hospital
Ralph McGuire
Affiliation:
Royal Edinburgh Hospital, Morningside Park, Edinburgh EH 10 SHF
*
∗ Correspondence
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the 'Save PDF' action button.

The presence of tardive dyskinesia in a sample of 43 patients with schizophrenia and 37 psychopaths who had been hospitalised for many years and exposed to large amounts of medication was assessed while testing their cognitive function. Subjects who showed no evidence of abnormal movements performed significantly better on the test of delayed recall, but there were no differences in performance on any of the other tests of cognitive function used. Multiple regression analysis revealed that age and the total lifetime dose of neuroleptic medication received (in chlorpromazine equivalents) were the only variables to predict the Abnormal Involuntary Movement Scale score, although a large amount of variance in this variable was unaccounted for. The duration of treatment with neuroleptics did not predict AIMS score.

Information

Type
Papers
Copyright
Copyright © 1986 The Royal College of Psychiatrists 

This journal is not currently accepting new eletters.

eLetters

No eLetters have been published for this article.